TECH

Bio-TechneC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-20

Current thesis

Bio-Techne's premium tools and diagnostics exposure is showing pockets of strength: large pharma has grown double digits for six straight quarters, spatial biology is still expanding quickly, and management says funding activity may be turning more constructive. If that broadens, revenue can reaccelerate and the stock could move toward the sell-side median target.

Posture

Mixed

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta +3.8.

What can break

Emerging biotech demand is still lagging, and management said broad-based demand has not yet materialized.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $49.00 · Bull $66.00 · Bear $36.00

Data freshness

Prices

As of 2026-07-20

Fundamentals

As of 2026-07-20 • Vendor: Data Vendor v1

Scores

As of 2026-07-20 • Model: HYBRID_IC_RP

AI Memo

As of 2026-05-19 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-20

Supporting evidence

What

Grade C · Mixed

Confidence Medium · Net Neutral

Target $70.33

Why

Momentum91 · Δ7d +3.8

Value60 · Δ7d -0.1

Sentiment16 · Δ7d -2.7

So what

Balanced signals (Net Neutral). Wait for confirmation before sizing up.

Lead driver: Momentum · See technicals

Momentum

26% active weight

Current posture

7d trendFlat

Δ7d

+3.8

Δ21d

+0.1

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.1

Δ21d

-0.2

Sentiment

34% active weight

Current posture

7d trendSoftening

Δ7d

-2.7

Δ21d

-2.6

Why this grade

Composite grade C. Momentum 91.3 / Value 60.5 / Sentiment 15.7

Fundamentals (TTM)

As of 2026-07-20

Market Cap

$11.22B

Beta

1.48

Shares Out

156.57M

P/E (TTM)

130.6

P/S (TTM)

8.07

P/FCF (TTM)

56.47

Rev YoY

-1.5%

EPS YoY

+128.1%

Gross Margin

+66.4%

Op Margin

+9.0%

Net Debt

$281.87M

Current Ratio

4.49

As of 2026-07-20 • Updated nightlySource: Internal modelMethodology